Celgene gains option for Triphase's epigenetic cancer therapy

By Sandi Wong | Jan 29, 2019 | 8:16 PM GMT

Celgene Corp. (NASDAQ:CELG) has acquired another option for a cancer program ahead of its acquisition by Bristol-Myers Squibb Co. (NYSE:BMY), this time via a

Read the full 249 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE